Lanwei Medical released its 2026 interim report, with net profit attributable to the parent company of 63.5938 million yuan. The company's total operating revenue was 592 million yuan, down 22.09% from the same period last year, a decrease of 168 million yuan. Net cash inflow from operating activities was 153 million yuan. The latest asset-liability ratio was 23.75%, gross margin was 27.24%, ROE was 4.10%, and diluted earnings per share was 0.16 yuan.
Shanghai Labway Clinical Laboratory Co LtdRevenue down 22.09% year-over-year, net profit 63.59 million yuan, indicating weaker financial performance.
